These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 29288529)

  • 1. Mitogen-activated protein kinase pathway inhibitors rescue lethal phenotypes in a BRAF gain-of-function Drosophila melanogaster model.
    Volkhardt A; Bohnekamp J; Pfeifle I; Engel C; Magin TM; Kunz M
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):545-548. PubMed ID: 29288529
    [No Abstract]   [Full Text] [Related]  

  • 2. MEK inhibitor cobimetinib rescues a dRaf mutant lethal phenotype in Drosophila melanogaster.
    Pfeifle I; Bohnekamp J; Volkhardt A; Kirsten H; Rohwedder A; Thum A; Magin TM; Kunz M
    Exp Dermatol; 2019 Sep; 28(9):1079-1082. PubMed ID: 31338879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discovery: inhibitors that activate.
    Cichowski K; Jänne PA
    Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
    Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
    Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
    [No Abstract]   [Full Text] [Related]  

  • 5. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobimetinib (GDC-0973, XL518).
    Andrlová H; Zeiser R; Meiss F
    Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF inhibitors that evade paradoxical MAPK pathway activation.
    Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
    Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
    Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
    Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
    Corazao-Rozas P; Guerreschi P; André F; Gabert PE; Lancel S; Dekiouk S; Fontaine D; Tardivel M; Savina A; Quesnel B; Mortier L; Marchetti P; Kluza J
    Oncotarget; 2016 Jun; 7(26):39473-39485. PubMed ID: 27250023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coordinating ERK/MAPK signalling through scaffolds and inhibitors.
    Kolch W
    Nat Rev Mol Cell Biol; 2005 Nov; 6(11):827-37. PubMed ID: 16227978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.
    Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A
    Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
    Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
    J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.